GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Loxo Oncology Inc (NAS:LOXO) » Definitions » Equity-to-Asset

Loxo Oncology (Loxo Oncology) Equity-to-Asset : 0.58 (As of Sep. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Loxo Oncology Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Loxo Oncology's Total Stockholders Equity for the quarter that ended in Sep. 2018 was $379.2 Mil. Loxo Oncology's Total Assets for the quarter that ended in Sep. 2018 was $659.2 Mil. Therefore, Loxo Oncology's Equity to Asset Ratio for the quarter that ended in Sep. 2018 was 0.58.

The historical rank and industry rank for Loxo Oncology's Equity-to-Asset or its related term are showing as below:

LOXO's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Equity-to-Asset only.

Loxo Oncology Equity-to-Asset Historical Data

The historical data trend for Loxo Oncology's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Loxo Oncology Equity-to-Asset Chart

Loxo Oncology Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17
Equity-to-Asset
-0.68 0.98 0.98 0.90 0.48

Loxo Oncology Quarterly Data
Sep13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 0.48 0.51 0.55 0.58

Competitive Comparison of Loxo Oncology's Equity-to-Asset

For the Biotechnology subindustry, Loxo Oncology's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Loxo Oncology's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Loxo Oncology's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Loxo Oncology's Equity-to-Asset falls into.



Loxo Oncology Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Loxo Oncology's Equity to Asset Ratio for the fiscal year that ended in Dec. 2017 is calculated as

Equity to Asset (A: Dec. 2017 )=Total Stockholders Equity/Total Assets
=378.21/783.442
=0.48

Loxo Oncology's Equity to Asset Ratio for the quarter that ended in Sep. 2018 is calculated as

Equity to Asset (Q: Sep. 2018 )=Total Stockholders Equity/Total Assets
=379.215/659.228
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Loxo Oncology  (NAS:LOXO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Loxo Oncology Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Loxo Oncology's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Loxo Oncology (Loxo Oncology) Business Description

Traded in Other Exchanges
N/A
Address
Loxo Oncology Inc develops medicines for patients with genetically defined cancers. Its approach is based on the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building inhibitors against single targets in the cancer cell. Its pipeline of products includes Larotrectinib, Loxo etc.
Executives
Jennifer Burstein officer: Senior VP of Finance C/O LOXO ONCOLOGY, INC., ONE LANDMARK SQUARE, SUITE 1122, STAMFORD CT 06901
Keith T. Flaherty director 55 FRUIT STREET, YAWKEY 9E, BOSTON MA 02114
Lori Anne Kunkel director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Joshua H. Bilenker director, officer: President & CEO C/O LOXO ONCOLOGY, INC., ONE LANDMARK SQUARE, SUITE 1122, STAMFORD CT 06901
Steve Elms director, 10 percent owner 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Alan Fuhrman director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Timothy M Mayleben director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Andrew N Schiff 10 percent owner PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Dennis J Purcell 10 percent owner AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Aisling Capital Iii Lp 10 percent owner 888 Seventh Avenue, 30th Fl, New York NY 10106
Aisling Capital Partners Iii Lp 10 percent owner AISLING CAPITAL LLC, 888 SEVENTH AVENUE 30TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iii Llc 10 percent owner AISLING CAPITAL LLC, 888 SEVENTH AVENUE 30TH FLOOR, NEW YORK NY 10106
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp V Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Loxo Oncology (Loxo Oncology) Headlines

From GuruFocus

Loxo Oncology to Announce Third Quarter 2018 Financial Results

By Marketwired Marketwired 11-01-2018

Loxo Oncology to Participate in Upcoming Investor Conferences

By Marketwired Marketwired 11-06-2018

Loxo Oncology to Present at Upcoming Investor Conferences

By Marketwired Marketwired 08-29-2018